جست‌وجوی استاد و پژوهشگر

Jette Sandholm Jensen Kastrupمشاهده پروفایل

استاد

• Structural Biology
• Drug Design
• Neuroscience
• +۴ مورد دیگر

Jette Sandholm Jensen Kastrup is Professor of Experimental Structure-Based Drug Design at the Department of Drug Design and Pharmacology, University of Copenhagen, where she also serves as Deputy Head of Department with research leadership responsibilities. She leads the Receptor Structural Biology group, focusing on molecular studies of ionotropic glutamate receptors (iGluRs) and G protein-coupled receptors (GPCRs) for neurological drug discovery. Education: M.Sc. in Pharmacy, Royal Danish School of Pharmacy (1986) PhD (Industrial PhD), Royal Danish School of Pharmacy/Cheminova A/S (1988) Research Focus: Her work integrates structural biology (X-ray crystallography), medicinal chemistry, and molecular pharmacology to study receptor-drug interactions. Primary interests include: structural mechanisms of iGluRs in neurological disorders (Alzheimer's, epilepsy), GPCR drug targeting (35% of approved drugs), and development of allosteric modulators. Recent work emphasizes kainate and AMPA receptor modulation for neurotherapeutic applications. Publication Trends: Recent articles (2023-2025) demonstrate advanced structural characterization of glutamate receptors (GluK1, GluD1, GluA2) using crystallography and biophysical methods, with emphasis on allosteric modulator design and receptor activation mechanisms. Studies frequently integrate computational modeling, mutagenesis, and functional assays to map drug-receptor interactions. Awards: Valborg and Edith Larsens Foundation Award (2005) Faculty of Pharmaceutical Sciences Award (2007) Leadership & Training: Directed the Drug Research Academy (2007-2012) and GluTarget excellence program (24.5M DKK grant). Mentored 32 PhD students and 15 postdocs. Currently heads the Neuroprotection research cluster and serves on national science councils including the Danish Council for Independent Research. Laboratory: Leads the Receptor Structural Biology group specializing in protein crystallography, collaborates internationally with medicinal chemists and pharmacologists, and maintains instrumentation for structural studies of membrane proteins.

Bente Frølundمشاهده پروفایل

استاد

• Pharmacology
• Medicinal Chemistry
• Neuropharmacology
• +۷ مورد دیگر

Bente Frølund is a Professor in the Department of Drug Design and Pharmacology at the Faculty of Health and Medical Sciences, University of Copenhagen. Her research focuses on neuropharmacology with emphasis on GHB/CaMK2 pharmacology and ionotropic GABA A receptors, as well as nACh receptors and GABA transporters. Her research interests include: GHB/CaMK2 pharmacology Ionotropic GABA A receptors Nicotinic acetylcholine receptors (nACh) GABA transporters (GAT and TauT) Structure-activity relationship studies Development of photoligands for protein localization and activation Engineered molecular probes for ligand-protein interactions Professor Frølund's recent publications demonstrate a strong focus on receptor pharmacology, particularly exploring the interactions between GHB ligands and CaMKIIα, as well as the development of novel ligands for GABA A and nicotinic acetylcholine receptors. Her work combines medicinal chemistry approaches with neuropharmacological evaluation to develop molecular tools for studying receptor function and potential therapeutic applications, with neuroprotection being a key focus area. Her scientific contributions include 178 research outputs as documented in her publication record, spanning journal articles, book chapters, patents, and conference presentations. Her work has been referenced in Wikipedia pages, picked up by news outlets, and discussed on social media platforms including X, Facebook, Bluesky, and Reddit. Professor Frølund collaborates extensively with researchers both within the University of Copenhagen and internationally, as indicated by the network visualization in her profile. Her laboratory develops molecular probes and novel methodologies to gain insight into the identity, localization, function, and therapeutic potential of target receptors and transporters.

• Pharmacology
• Chemokine Receptors
• GPCR Signaling
• +۳ مورد دیگر

Olav Larsen is a Research Fellow in the Department of Drug Design and Pharmacology (Pharmaceutical Informatics) at the University of Copenhagen, where he conducts advanced research in pharmacology and receptor biology. His work primarily focuses on G protein-coupled receptors (GPCRs), chemokine signaling, and ligand-receptor interactions. His research interests span: GPCR Pharmacology : Investigating biased signaling pathways and ligand design for Class A GPCRs. Chemokine Receptor Dynamics : Studying motif conservation, allosteric modulation, and peptide-derived regulation in receptors like CCR1, CCR5, and CCR7. Therapeutic Targeting : Exploring implications for diabetes, inflammation, and immune disorders through receptor-specific mechanisms. Analysis of his recent publications reveals a consistent focus on structural and functional aspects of receptor-ligand interactions, with emphasis on: Molecular mechanisms enabling ligand discrimination in chemokine receptors Biased agonism in metabolic hormone receptors (GLP-1R) Computational and experimental approaches to receptor modeling This work contributes to foundational knowledge in drug design and cellular signaling.

• Neuromedicinal Chemistry
• Structure-Activity Relationship (SAR) Studies
• Organic Synthesis
• +۳ مورد دیگر

Rasmus Prætorius Clausen serves as Professor of Medicinal Chemistry within the Department of Drug Design and Pharmacology at the University of Copenhagen's Faculty of Health and Medical Sciences. His research program focuses on neuromedicinal chemistry, specializing in biostructure-based SAR studies, organic synthesis, and development of NMDA receptor ligands with therapeutic potential for neurological disorders. Dr. Clausen's educational background includes a PhD in Organic Chemistry from Aarhus University (1999) with dissertation "Silicon in Organic Chemistry: New Tri- and Tetraalkoxysilanes," and a Cand. Scient. in Chemistry-Cell Biology from the University of Southern Denmark (1994). His academic journey established the foundation for his current work at the chemistry-neuroscience interface. His research interests center on precise targeting of NMDA receptor subtypes through rational molecular design. Key areas include developing GluN2-subunit selective glycine site agonists, investigating allosteric modulation mechanisms, and optimizing molecular geometry for enhanced potency and selectivity. This work bridges synthetic organic chemistry with neuropharmacology to create tools for studying glutamate receptor function and potential therapeutics. Analysis of his recent publications (2020-2025) reveals a consistent trajectory in NMDA receptor pharmacology, with increasing sophistication in subunit-specific targeting. His work demonstrates strong translational potential, particularly in developing compounds with improved pharmacokinetic profiles like the GluN2C-selective agonist prodrugs characterized in 2023. Dr. Clausen's research impact is evidenced by substantial citation metrics, including 39 Scopus citations for his 2021 PNAS paper on GHB analogs and neuroprotection. His work reaches broad audiences, with publications shared across academic networks and read by dozens of researchers on platforms like Mendeley. As a laboratory leader, he maintains active collaborations both within Denmark and internationally, reflected in his co-authorship patterns. His team focuses on the medicinal chemistry pipeline from molecular design through synthesis to pharmacological characterization, with particular emphasis on creating selective neuropharmacological tools.

Jacob Emil Petersenمشاهده پروفایل

پژوهشگر ارشد

• GPCR Signaling
• Obesity Treatment
• Metabolic Diseases
• +۴ مورد دیگر

Jacob Emil Petersen is a Postdoctoral Researcher in the Schwartz Group at the Center for Basic Metabolic Research (CBMR), Faculty of Health and Medical Sciences, University of Copenhagen. His work focuses on G protein-coupled receptors (GPCRs) and their role in metabolic regulation and disease pathogenesis. Dr. Petersen's research spans multiple disciplines within molecular pharmacology and metabolism. His primary focus is on tachykinin receptors (NK1 and NK2), free fatty acid receptors (FFAR1/FFAR4), and other GPCRs involved in energy homeostasis. He employs a multidisciplinary approach combining structural biology, molecular pharmacology, and in vivo studies to investigate receptor activation mechanisms, signaling bias, and develop novel therapeutic strategies for obesity and metabolic disorders. His work has contributed to understanding how neuropeptides interact with their receptors and how these interactions can be leveraged for therapeutic benefit. Analysis of Dr. Petersen's publications reveals a consistent trajectory toward understanding receptor signaling mechanisms with direct therapeutic applications. His research increasingly integrates neuroscience, endocrinology, and pharmacology to address complex metabolic disorders. The publications show strong collaboration with interdisciplinary teams and have appeared in high-impact journals including Nature and Journal of Biological Chemistry, with several papers receiving significant media attention and citations. As a member of the Schwartz Group at CBMR, Dr. Petersen contributes to one of Europe's leading research environments for metabolic disease research. The group focuses on understanding the molecular mechanisms underlying metabolic disorders and developing innovative therapeutic approaches. His work has practical implications for the development of new pharmacotherapies targeting GPCRs for obesity, diabetes, and related metabolic conditions, with several publications highlighting potential novel treatment strategies.

Pablo Artigasمشاهده پروفایل

استاد

• Membrane Biophysics
• Ion Transport
• P-type ATPases
• +۵ مورد دیگر

Dr. Pablo Artigas serves as Professor in the Department of Cell Physiology and Molecular Biophysics at Texas Tech University Health Sciences Center's School of Medicine. His research program centers on elucidating the molecular mechanisms of P-type ATPase ion pumps, with particular focus on sodium/potassium (Na/K) and proton/potassium (H/K) transporters critical for cellular homeostasis and implicated in multiple human diseases. His laboratory investigates three interconnected research domains: Mechanisms of ion selectivity and transport stoichiometry in Na/K and H/K pumps using structural biology and electrophysiology Pathophysiological consequences of pump mutations in diseases including Conn's syndrome, Charcot-Marie-Tooth type 2, alternating hemiplegia of childhood, and cystic fibrosis Evolutionary adaptations of ion transport systems in extreme environments, modeled through brine shrimp survival in 14% salinity (4x seawater) Analysis of Dr. Artigas's recent publications (2020-2023) reveals a consistent emphasis on resolving atomic-level mechanisms of ion recognition and transport through integrated approaches combining mutagenesis, voltage clamp fluorometry, and computational modeling. His work demonstrates how subtle structural changes in transmembrane domains govern ion specificity and electrogenicity, with direct implications for understanding disease pathogenesis. Dr. Artigas currently mentors three graduate students and two undergraduates, supported by active NIH, NSF, and CH Foundation grants. His laboratory operates within the Center for Membrane Research (CMPR) and utilizes the Membrane Protein Core Laboratory (MPCL) facilities, providing access to advanced electrophysiology rigs, molecular biology suites, and fluorescence imaging systems. The lab maintains active collaborations with leading institutions including Aarhus University (Denmark), University of Chicago, and University of Iowa, fostering an international research environment focused on membrane transport biology.

Michaela Jansenمشاهده پروفایل

استاد

• Membrane protein structure and function
• Neurotransmitter receptors
• Pentameric ligand-gated ion channels
• +۴ مورد دیگر

Dr. Michaela Jansen is a Professor and Associate Dean for Medical Education and Accreditation at the Texas Tech University Health Sciences Center School of Medicine. She holds appointments in the Department of Cell Physiology and Molecular Biophysics, serves as Affiliate Faculty in Biotechnology, and is Associate Faculty in Translational Neuroscience and Pharmacology. Dr. Jansen directs the Jansen Laboratory within the Center for Membrane Protein Research. Dr. Jansen's research focuses on the structure and function of membrane transport proteins, particularly neurotransmitter receptors of the pentameric ligand-gated ion channel superfamily (nAChR, 5HT3, GABA) and the proton-coupled folate transporter (PCFT). Her work investigates how these proteins function as therapeutic targets for neurological disorders and cancer chemotherapy. She employs a multidisciplinary approach combining molecular biology, biochemistry, chemical biology, biophysics, and pharmacology to study these membrane proteins at a molecular level. Analysis of Dr. Jansen's recent publications (2019-2024) reveals a consistent focus on serotonin receptors (particularly 5-HT3A), protein chaperones like RIC-3, and the proton-coupled folate transporter. Her research has important implications for understanding neurological disorders and developing cancer therapeutics. The work spans structural biology, molecular pharmacology, and translational applications, demonstrating both fundamental scientific contributions and potential clinical relevance. Dr. Jansen has received significant research funding, including continuous support from the National Institute of Neurological Disorders and Stroke from 2007 through 2025, as well as funding from The CH Foundation and South Plains Foundation. She had a News and Views feature published in Nature, highlighting the significance of her contributions to membrane protein research. Dr. Jansen has mentored numerous graduate students and postdocs, with past trainees securing positions at prestigious institutions including Columbia, Einstein, Vanderbilt, and Yale, as well as in the pharmaceutical industry at companies like Johnson & Johnson, Moderna, and Sanofi. Current lab members include postdocs, graduate students, and undergraduate researchers working on various aspects of membrane protein structure and function. The Jansen Laboratory provides a collaborative research environment focused on understanding membrane proteins through cutting-edge techniques. The lab culture emphasizes diversity and inclusion, with a commitment to the strength gained through unity in diversity, reflecting Dr. Jansen's dedication to creating an inclusive research environment.

Christina M. Davisمشاهده پروفایل

مدرس

• Organic Chemistry
• Supramolecular Chemistry
• Photochemistry
• +۳ مورد دیگر

Christina M. Davis serves as a Lecturer in the Department of Chemistry at Valparaiso University, where she contributes to both teaching and research in organic and supramolecular chemistry disciplines. Educational background: Ph.D. in Organic Chemistry – University of Texas (2014) B.S. – College of William and Mary (2010) Her research program centers on supramolecular recognition systems and photoresponsive materials , with particular focus on tetrathiafulvalene-calix[4]pyrrole architectures. Current investigations examine ion-regulated binding of fullerenes, photoinduced electron transfer in porphyrin-containing ensembles, and fluorescence modulation in photochromic nanoparticle systems. This work bridges synthetic organic chemistry with photophysical characterization to develop stimuli-responsive molecular devices. Publication analysis reveals consistent output in high-impact chemistry journals between 2011-2014, demonstrating expertise at the intersection of organic synthesis, nanomaterials, and photophysics. Her research shows particular strength in designing supramolecular systems with tunable electronic properties for potential sensing applications. Scientific Awards: No specific awards documented in available materials Advising and Resources: Active research program evidenced by recent publications Collaborative work with multiple co-investigators Membership in American Chemical Society No explicit information on current students or grant funding Research activities appear integrated within the Department of Chemistry infrastructure without indication of a separately named laboratory facility.

Andrew Pickeringمشاهده پروفایل

دانشیار

• Aging
• Proteostasis
• Neurodegenerative Diseases
• +۵ مورد دیگر

Andrew Pickering, Ph.D., is an Associate Professor in the Department of Integrative Biology and Pharmacology at McGovern Medical School, UTHealth Houston. He directs the Geroscience Core at the Institute on Aging, overseeing initiatives like the Annual Symposium on Aging Research and the Harry E. Bovay, Jr. Foundation Pilot Grants Program, which funds junior faculty in aging research. His research centers on proteostasis in aging and neurodegeneration. Key areas include: Proteasome dysfunction in Alzheimer's disease and development of proteasome-activating therapeutics Mitochondrial thioredoxin systems as metabolic regulators and lifespan extenders Protein translation dynamics, where early-life repression extends lifespan via juvenile hormone pathways Cross-species mechanisms of aging using Drosophila, mice, and comparative biology His recent publications (2019-2024) focus on proteasome augmentation therapies for Alzheimer's, translational regulation of aging, mitochondrial metabolism, and microbiome impacts on neurodegeneration. These reflect a consistent theme: targeting proteostatic mechanisms to combat age-related functional decline. Dr. Pickering leads the Pickering Aging Lab, investigating aging drivers through biochemical, genetic, and pharmacological approaches. The lab collaborates with clinical researchers to translate findings into therapeutic strategies for age-related diseases.

• Pharmaceutical Sciences
• Pharmacology
• Toxicology
• +۵ مورد دیگر

Björn Kull serves as Head of Department for Joint Operational Support within the Department for Research Support and External Relations at Karolinska Institutet, one of Europe's foremost medical universities. He earned his Doctoral Degree of Medicine from Karolinska Institutet's Department of Physiology and Pharmacology in 2000, establishing a strong foundation for his career in academic research and administration. Professor Kull's research expertise spans pharmaceutical sciences, pharmacology, toxicology, and neurosciences, with a particular focus on adenosine receptor pharmacology and its interactions with dopamine signaling pathways. His work has significantly contributed to understanding receptor signaling mechanisms in the central nervous system. Analysis of his publication record from 1996-2012 reveals a consistent focus on adenosine receptors, particularly the A2A subtype, and their interactions with dopamine receptors. His research trajectory shows progression from basic receptor characterization to more complex studies of receptor interactions and signaling pathways, demonstrating increasing sophistication in experimental approaches over time. While no specific scientific awards are mentioned in the available information, Professor Kull's publication record in high-impact journals such as Nature Biotechnology, Molecular Pharmacology, and Neuroscience indicates recognition within his field. His transition from active research to research administration reflects a career evolution common among senior academics who apply their scientific expertise to institutional leadership. In his current administrative role, Professor Kull oversees research support operations at Karolinska Institutet, leveraging his deep understanding of the research process to facilitate scientific discovery across the institution. His leadership contributes to maintaining Karolinska Institutet's position at the forefront of medical research.

Roger Estrada Weaverمشاهده پروفایل

استاد

• RNA Biochemistry
• Heterocyclic Compound Chemistry
• Drug Discovery
• +۷ مورد دیگر

Roger Estrada Weaver is a Full Professor at the IQS School of Engineering, Universitat Ramon Llull, where he works in the Department of Organic and Pharmaceutical Chemistry as part of the Pharmaceutical Chemistry Group. He maintains an active research profile with an h-index of 749 and has been involved in numerous research projects since 2007. His research focuses on RNA Biochemistry, Heterocyclic Compound Chemistry, Drug Discovery, Small Molecule Biochemistry, and targeted cancer therapies. He has made significant contributions to the development of CXCR4 inhibitors, IRAK4 degraders, and compounds targeting pathogenic RNA structures, with particular emphasis on treatments for lymphoma and other hematological malignancies. His recent publications demonstrate a strong trend toward computational and molecular approaches to drug design, particularly for cancer therapeutics. His work integrates molecular modeling with synthetic chemistry to develop novel compounds targeting specific pathways in malignancies, with increasing focus on precision medicine approaches for hematological cancers. Professor Weaver leads the GQF: Grup de Química Farmacèutica research group and is Principal Investigator for several significant projects including DisX4lymph (focused on CXCR4 allosteric inhibitors and IRAK4 degraders for B-cell lymphoma treatment) and PROTEOblood (a Franco-Spanish cooperative network for proteinopathy analysis and development of individualized therapies in hematological cancers). His research has been funded by the Agencia Estatal de Investigación, Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR), European Commission, and Universitat Ramon Llull. His laboratory work centers around the Pharmaceutical Chemistry Group at IQS, where his team develops innovative approaches to target RNA structures and protein interactions in cancer. Current research directions include covalent reversible inhibitors of IRAK4, non-symmetrical CXCR4 inhibitors, structural simplification methods for hit discovery, and photochemical synthesis techniques for heterocyclic compounds with therapeutic potential.